Peptide Libraray

RL2

General Information

DRACP ID DRACP00592

Peptide Name RL2

Sequence RLLRLLRLRRLLRL

Sequence Length 14

UniProt ID Not available

PubChem CID Not available

Origin Synthetic

Type Synthetic peptide

Classification

Active ACP

Activity Information

Cell Line	Disease	Cancer Classified	Activity	Assay	Testing Time	Literature
HeLa	Human papillomavirus-related endocervical adenocarcinoma	Carcinoma	IC50=4.3±0.2 μM	MTT assay	24h	1
MCF-7	Invasive breast carcinoma of no special type	Carcinoma	IC50=4.5±0.3 μM	MTT assay	24h	1
A549	Lung adenocarcinoma	Carcinoma	IC50=4.8±0.6 μM	MTT assay	24h	1

Hemolytic Activity Mice red blood cells: HD50>200 μM

Normal (non-cancerous) Cytotoxicity HLF: IC50=21.4±1.3 μM; 293T: IC50=41.6±2.7 μM; HUVEC: IC50=19±1.5 μM

Target Not available

Affinity Not available

Mechanism Not available

Nature Anticancer

Structure Information

PDB ID Not available

Predicted Structure DRACP00592

Helicity Not available

Linear/Cyclic Linear

Disulfide/Other Bond Not available

N-terminal Modification Free

C-terminal Modification Amidation

Other Modification None

Chiral L

Physicochemical Information

Formula C84H162N32O15

Absent amino acids ACDEFGHIKMNPQSTVWY

Common amino acids L

Mass 209248

Pl 13.2

Basic residues 6

Acidic residues 0

Hydrophobic residues 8

Net charge 6

Boman Index -5016

Hydrophobicity 24.29

Aliphatic Index 222.86

Half Life
Mammalian: 1.3 hour
Yeast: 3 min
E.coli: 2 min

Extinction Coefficient cystines 0

Absorbance 280nm 0

Polar residues 0

Amino acid distribution

Literature Information

Literature 1

Pubmed ID 27195657

Title Amphipathicity Determines Different Cytotoxic Mechanisms of Lysine- or Arginine-Rich Cationic Hydrophobic Peptides in Cancer Cells

Doi 10.1021/acs.jmedchem.5b02016

Year 2016

Patent

Patent ID Not available

Patent Title Not available

Other Iinformation Not available

Other Published ID Not available